Discover Insights on Our Deep Tech Commercialisation Blog

Whether you are commercialising university research, raising investment for a biotechnology start-up, licensing a new technology, or evaluating an innovation portfolio, understanding the value of your intellectual property (IP) is essential. Intellectual property often represents the most valuable asset in a technology-based business. However, determining its true value requires far more than estimating development costs or assigning a value to a patent. Effective IP valuatio

One of the most important questions every deep-tech founder will eventually face is simple: what is the company actually worth? For biotech and deep-tech startups, this can be difficult to answer. Many companies are still pre-revenue and operate in highly technical sectors characterised by long development timelines, regulatory complexity, and significant capital requirements. However, valuation plays a critical role in shaping investment discussions. It influences investor c

For many deep-tech and biotech startups, intellectual property is not just part of the business. It is the business. Unlike traditional companies, early-stage deep-tech ventures often have limited physical assets or revenue. Their real value lies in: patents, proprietary processes, platform technologies, specialised know-how, scientific data, and technical expertise. Yet many founders do not fully understand the commercial value of their intellectual property. This creates ri

Many deep-tech and biotech founders believe that strong science will naturally attract funding and commercial success. Unfortunately, this is rarely the case. In reality, investors are not only evaluating the quality of the technology. They are assessing whether the innovation can become a scalable, sustainable business. A scientifically impressive product may still struggle commercially because of: high manufacturing costs, regulatory complexity, unclear market demand, limit

At the heart of every successful deep-tech startup lies more than breakthrough science; it lies in financial clarity. During several engagements with entrepreneurs, Maravion immersed them in a dynamic Financial Masterclass designed to turn brilliant innovations into investable, sustainable ventures. In a sector known for its long development timelines and high capital intensity, this session addressed the one skill most founders often overlook: financial fluency. Aligning Sci

At Maravion, we help deep-tech, biotech, pharmaceutical, and innovation-driven companies become investment-ready through rigorous valuation, techno-economic analysis, and commercial due diligence. In highly technical sectors where businesses are often built around intellectual property, scientific know-how, and emerging technologies, investors require more than promising research. They need confidence that the innovation can scale commercially, navigate regulatory pathways, a

At Maravion, we believe that building scalable deep-tech ventures, whether in biotech, clean tech, agritech, or advanced materials, requires more than just technical brilliance. It demands financial discipline, strategic foresight, and an unrelenting commitment to sustainable innovation. In our recent session, “Scaling a Deep-Tech Venture in Emerging Markets,” we shared practical frameworks for navigating the complex journey from lab bench to market. Whether you're developi